SILEXION THERAPEUTICS CORP Liabilities, Fair Value Adjustment
SILEXION THERAPEUTICS CORP (SLXN) reported Liabilities, Fair Value Adjustment of -$154.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:LiabilitiesFairValueAdjustment · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP liabilities, fair value adjustment for the quarter ending 2026-06-30 was -$154.00K, a 177.78% decline year-over-year.
- SILEXION THERAPEUTICS CORP liabilities, fair value adjustment for the quarter ending 2026-03-31 was -$15.00K, a 118.99% decline year-over-year.
- SILEXION THERAPEUTICS CORP liabilities, fair value adjustment for the quarter ending 2025-12-31 was $29.00K.
- SILEXION THERAPEUTICS CORP liabilities, fair value adjustment for the quarter ending 2025-09-30 was -$27.00K.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$154.00K 10-Q · filed 2026-08-14 | -$169.00K 10-Q · filed 2026-08-14 | -$140.00K derived: sum of 3 quarters · filed 2026-08-14 | -$167.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$15.00K S-1/A · filed 2026-08-10 | $14.00K derived: sum of 2 quarters · filed 2026-08-10 | -$13.00K derived: sum of 3 quarters · filed 2026-08-10 | $185.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $29.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $2.00K derived: sum of 2 quarters · filed 2026-08-10 | $200.00K derived: sum of 3 quarters · filed 2026-08-14 | $279.00K S-1/A · filed 2026-08-10 |
| 2025-09-30 | -$27.00K 10-Q · filed 2025-11-12 | $171.00K derived: sum of 2 quarters · filed 2026-08-14 | $250.00K 10-Q · filed 2025-11-12 | $19.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $198.00K 10-Q · filed 2026-08-14 | $277.00K 10-Q · filed 2026-08-14 | $46.00K derived: sum of 3 quarters · filed 2026-08-14 | -$1.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $79.00K S-1/A · filed 2026-08-10 | -$152.00K derived: sum of 2 quarters · filed 2026-08-10 | -$1.22M derived: sum of 3 quarters · filed 2026-08-10 | -$1.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | -$231.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | -$1.29M derived: sum of 2 quarters · filed 2026-08-10 | -$1.23M derived: sum of 3 quarters · filed 2026-08-10 | -$1.15M S-1/A · filed 2026-08-10 |
| 2024-09-30 | -$1.06M 10-Q · filed 2025-11-12 | -$1.00M derived: sum of 2 quarters · filed 2025-11-12 | -$919.00K 10-Q · filed 2025-11-12 | -$830.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $64.00K 10-Q · filed 2025-08-12 | $145.00K 10-Q · filed 2025-08-12 | $234.00K derived: sum of 3 quarters · filed 2025-08-20 | $234.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-03-31 | $81.00K 10-Q · filed 2025-05-13 | $170.00K derived: sum of 2 quarters · filed 2025-08-20 | $170.00K derived: sum of 3 quarters · filed 2025-08-20 | $168.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2023-12-31 | $89.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-08-20 | $89.00K derived: sum of 2 quarters · filed 2025-08-20 | $87.00K derived: sum of 3 quarters · filed 2025-08-20 | $86.00K 8-K · filed 2025-08-20 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | -$2.00K derived: sum of 2 quarters · filed 2024-11-14 | -$3.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$2.00K 10-Q · filed 2024-08-29 | -$3.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |